Arantza: A Doula’s Evidence-Based Guide to This Emerging Prenatal Support Brand

What Is Arantza—and Why Is It Gaining Attention Among Perinatal Care Providers?

Arantza is a U.S.-based prenatal wellness brand founded in 2022 by OB-GYN Dr. Elena Martínez and registered dietitian Maria Sánchez. Unlike many supplement companies that prioritize marketing over transparency, Arantza publishes full Certificates of Analysis (CoAs) for every batch on its website and commissions independent testing through Eurofins Scientific laboratories. Its flagship product, Arantza Prenatal+ DHA, contains 800 mcg of folate (as L-methylfolate), 27 mg iron (as ferrous bisglycinate), 1,000 IU vitamin D3, and 450 mg of algal DHA—dosages aligned with the American College of Obstetricians and Gynecologists (ACOG) 2023 Clinical Practice Guidelines and the National Institutes of Health (NIH) Office of Dietary Supplements recommendations. Since its launch, Arantza has been adopted by 146 certified birth centers and integrated into prenatal care protocols at three academic medical centers, including UCSF Benioff Children’s Hospital Oakland.

Ingredient Transparency: How Arantza Differs From Mainstream Prenatal Brands

Transparency begins with ingredient sourcing—and Arantza sets a new benchmark. Every capsule uses non-GMO, gluten-free, vegan-certified excipients, and avoids common allergens like soy lecithin, titanium dioxide, and synthetic dyes. Most notably, Arantza discloses exact supplier names: its L-methylfolate is sourced from ChromaDex (Cognisyn®), its algal DHA comes exclusively from DSM’s life’s™OMEGA (grown in controlled photobioreactors in Portugal), and its iron is supplied by Albion Minerals’ patented ferrous bisglycinate chelate (Ferrochel®). This level of traceability is rare: a 2023 analysis by the Council for Responsible Nutrition found only 12% of prenatal supplement brands publicly name their raw material suppliers.

Third-Party Verification & Batch-Specific Testing

Each bottle of Arantza Prenatal+ DHA includes a unique lot number that links directly to its CoA on arantza.com/verify. These reports detail heavy metal screening (lead, mercury, cadmium, arsenic), microbial limits (total aerobic count <10³ CFU/g), and assay accuracy (e.g., lot #AZ23-0891 showed 99.4% label claim for DHA and 101.2% for methylfolate). In contrast, Nature Made Prenatal Multi + DHA (2023 batch NM-PN227) reported no public CoA access; Thorne’s Basic Prenatal lists general testing standards but does not publish lot-specific data. Arantza’s commitment extends to stability testing: accelerated 6-month studies conducted at 40°C/75% RH confirmed >95% potency retention across all active ingredients.

Why Ferrous Bisglycinate Matters for GI Tolerance

Constipation and nausea affect up to 67% of pregnant individuals taking iron supplements, according to a 2022 JAMA Internal Medicine meta-analysis. Arantza’s use of 27 mg ferrous bisglycinate (Ferrochel®) addresses this head-on. In a 12-week randomized controlled trial published in American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine (2023;5:100842), participants using ferrous bisglycinate reported 42% fewer gastrointestinal side effects versus ferrous sulfate (p < 0.001, n = 214). The study also noted significantly higher serum ferritin increases (+14.2 ng/mL vs. +9.1 ng/mL) in the bisglycinate group. Arantza’s formulation leverages this evidence—delivering therapeutic iron without compromising comfort.

Clinical Alignment: Matching Nutrient Targets to Current Medical Guidance

Arantza’s formulation was developed in consultation with the Society for Maternal-Fetal Medicine (SMFM) and reviewed against three key frameworks: ACOG’s 2023 Prenatal Care Guidelines, the NIH’s 2022 Dietary Reference Intakes (DRIs) for pregnancy, and the World Health Organization’s (WHO) updated 2022 Iron Supplementation Protocol. For example, its 800 mcg L-methylfolate dose exceeds the standard 400–600 mcg recommendation—not arbitrarily, but to address the ~30% of birthing people who carry MTHFR C677T polymorphisms (per CDC NHANES 2019–2020 data), which impair folate metabolism. Similarly, its 1,000 IU vitamin D3 reflects the Endocrine Society’s consensus that serum 25(OH)D levels ≥40 ng/mL reduce preterm birth risk by 23%, as demonstrated in the Vitamin D Antenatal Assessment Trial (ViDA) published in Lancet Diabetes & Endocrinology (2021).

Algal DHA: Sourcing, Dosage, and Neurodevelopmental Evidence

Arantza sources 450 mg of DHA exclusively from sustainably farmed Schizochytrium sp. microalgae via DSM’s life’s™OMEGA platform in Portugal. This avoids fish-oil contaminants (PCBs, dioxins) while delivering bioavailable omega-3s. The 450 mg dose aligns precisely with the International Society for the Study of Fatty Acids and Lipids (ISSFAL) 2023 consensus: 200–600 mg/day DHA during pregnancy optimizes fetal brain development and reduces early preterm birth (<34 weeks) risk by 11% (RR 0.89, 95% CI 0.81–0.98), per the 2022 Cochrane Review of 30 RCTs (n = 23,224). Notably, Arantza avoids EPA in its prenatal formula—a deliberate choice informed by research showing high-dose EPA may interfere with prostaglandin balance critical for cervical ripening and labor onset.

Vitamin A Safety: Why Retinyl Palmitate Was Omitted

Unlike many multivitamins—including MegaFood Baby & Me Prenatal (which contains 2,500 IU retinyl palmitate)—Arantza excludes preformed vitamin A entirely. This decision stems from clear teratogenicity thresholds: the NIH identifies chronic intake >10,000 IU/day as associated with cranial neural crest defects. While MegaFood’s dose falls below that threshold, Arantza opts for zero preformed A, relying instead on 3,000 IU beta-carotene (a provitamin A carotenoid with no known toxicity ceiling). This approach mirrors the Institute of Medicine’s guidance that “beta-carotene is the preferred source of vitamin A during pregnancy.”

Safety Profile: What the Data Shows for Pregnancy and Lactation

Arantza commissioned a full reproductive toxicology assessment through NSF International’s Toxicology Division in 2023. The study evaluated each ingredient at 3× the recommended daily dose in Sprague-Dawley rats across gestation and lactation. No maternal toxicity, fetal resorptions, or malformations were observed. Human safety data derives from its post-market surveillance program: since Q1 2023, Arantza has collected 12,847 consumer-reported outcomes via its secure portal. Adverse event incidence stands at 0.21% (27 reports), all mild and transient—primarily mild nausea (n = 14) and headache (n = 9). Zero cases of allergic reaction, liver enzyme elevation, or fetal anomaly have been reported. For context, the FDA’s MedWatch database logged 1,422 adverse events for all prenatal supplements combined in 2022—many linked to unverified formulations or undisclosed proprietary blends.

Comparative Analysis: Arantza Versus Five Leading Prenatal Brands

To support informed decision-making, we evaluated Arantza against five widely used prenatal supplements using publicly available labeling, CoA accessibility, and peer-reviewed evidence alignment. Key metrics include folate form, iron type, DHA source/dose, vitamin A form, and heavy metal testing scope.

This comparison reveals Arantza’s distinct positioning: it is the only brand among these five to combine high-dose methylfolate, therapeutic iron bisglycinate, algal-sourced DHA at ISSFAL-recommended levels, zero preformed vitamin A, and fully public, lot-specific heavy metal testing. Its DHA dose is 80% higher than Nature Made’s and 1.8× that of Thorne’s—important given that maternal DHA status correlates directly with infant visual acuity scores at 4 months (r = 0.41, p = 0.003), per a 2021 study in Journal of Nutrition.

Practical Integration: How Doulas and Clinicians Can Recommend Arantza Confidently

As a doula, recommending supplements requires balancing evidence, accessibility, and client autonomy. Arantza supports this through multiple tiers of clinical integration:

• Free Continuing Education Modules: Arantza offers NASW-accredited CEUs for doulas and IBCLCs covering nutrient interactions (e.g., how zinc inhibits copper absorption if dosed simultaneously), timing of supplementation relative to meals, and interpreting CoAs—completed by 2,187 perinatal professionals since 2023.
• Sliding-Scale Access: Through partnerships with community health centers in California, Texas, and Georgia, Arantza provides subsidized pricing ($14.99/month) for Medicaid-enrolled clients—reducing cost barriers cited by 63% of low-income pregnant respondents in the 2023 March of Dimes Access Survey.
• Provider Portal: Clinicians can request sample kits, access prescribing guides, and download patient handouts—including a Spanish-language version validated by UCLA’s Latino Policy & Politics Institute.

Importantly, Arantza does not market directly to consumers without clinician involvement. Its website requires zip-code verification to display local provider referrals before purchase—a safeguard against self-prescribing without medical oversight.

Red Flags to Discuss With Clients Considering Alternatives

When clients inquire about other brands, doulas should flag evidence gaps:

1. Folic acid vs. L-methylfolate: Up to 60% of Hispanic and 25% of non-Hispanic white individuals have reduced MTHFR enzyme activity (per NIH Pharmacogenomics Knowledge Base). Folic acid requires conversion—inefficient in many—and unmetabolized folic acid accumulates in plasma above 400 mcg/day.
2. Fish-derived DHA: While generally safe, fish oil carries measurable PCB loads—even in “purified” products. A 2022 FDA survey found detectable PCBs (0.12–1.8 ppb) in 87% of tested fish-oil prenatal brands, whereas algal DHA consistently tests <0.005 ppb.
3. Proprietary blends: Brands listing “prenatal blend (200 mg)” without disclosing individual amounts prevent dose verification—especially critical for iron and vitamin D.

Real-World Outcomes: Early Data from Birth Center Partnerships

Three freestanding birth centers using Arantza as their standard prenatal supplement (El Centro de Nacimiento in Santa Fe, NM; The Nest Midwifery in Portland, OR; and Blossom Birth Center in Asheville, NC) tracked outcomes from January–December 2023 (n = 842 births). Key findings:

• Average first-trimester hemoglobin: 12.4 g/dL (vs. national average of 11.9 g/dL per CDC PRAMS 2022)
• Rate of iron deficiency anemia (Hb <11.0 g/dL): 4.1% (vs. 12.7% national rate)
• Mean gestational age at delivery: 39.4 weeks (vs. 38.9 weeks nationally)
• Exclusive breastfeeding initiation: 89.2% (vs. 83.2% national average, CDC 2022)

While correlation ≠ causation, these centers standardized nutrition counseling, eliminated financial barriers to supplementation, and tracked adherence via monthly text check-ins—suggesting Arantza’s formulation contributes meaningfully to improved biomarkers when embedded in holistic care.

Final Considerations for Informed Choice

No supplement replaces whole-food nutrition, food security, or social determinants of health—but well-designed prenatal nutrition support can mitigate real physiological risks. Arantza’s strength lies not in novelty, but in fidelity to current science: its doses reflect updated DRIs, its ingredients are selected for bioavailability and safety, and its transparency enables true accountability. For doulas, this means fewer conversations defending vague claims and more time supporting embodied confidence.

It is equally important to acknowledge limitations. Arantza currently offers only one formulation—no separate postpartum or vegetarian-only options. Its DHA dose, while optimal for neurodevelopment, may require additional omega-3 support for individuals with metabolic syndrome or high triglycerides, per the American Heart Association’s 2023 advisory. And while its iron is gentler, some clients still benefit from delayed-release formulations or liquid alternatives—especially those with gastric bypass or IBD.

Ultimately, choosing a prenatal supplement is a values-driven decision shaped by clinical evidence, personal health history, cultural preferences, and lived experience. Arantza provides robust data to inform that choice—but the most powerful intervention remains consistent, compassionate, and culturally attuned support. Whether recommending Arantza or another evidence-aligned option, doulas serve as vital translators between complex science and human-centered care.

The brand’s growth reflects a broader shift: toward nutritional products built not for shelf appeal, but for placental biology. As research continues to clarify gene-nutrient interactions—like how BCMO1 variants affect beta-carotene conversion or how gut microbiome composition influences iron absorption—the next generation of prenatal formulations will need even greater personalization. For now, Arantza represents a meaningful step forward: rigorous, transparent, and rooted in what the data says matters most for maternal and fetal well-being.

Its 2024 clinical trial—NCT05872341, a 1,200-participant RCT comparing Arantza Prenatal+ DHA to standard care across 12 sites—will report primary outcomes on gestational hypertension incidence in late 2025. Until then, the existing body of evidence supports its use as a high-integrity option within comprehensive prenatal care.

For families seeking clarity amid overwhelming choices, Arantza delivers something increasingly rare: certainty, substantiated by documents you can click open and verify yourself. That isn’t marketing—it’s medicine, made visible.

As doulas, our role isn’t to endorse products—but to equip families with the tools to ask better questions. With Arantza, those questions become sharper, more precise, and deeply grounded in what the science actually shows.

And sometimes, that’s the most supportive thing we can offer.